3
|
Hazlewood GS, Bombardier C, Li X, Movahedi M, Choquette D, Coupal L, Bykerk V, Schieir O, Mosher D, Marshall DA, Bernatsky S, Spencer N, Richards DP, Proulx L, Barber CEH. Heterogeneity in patient characteristics and differences in treatment across four Canadian rheumatoid arthritis cohorts. J Rheumatol 2021; 49:16-25. [PMID: 34334357 DOI: 10.3899/jrheum.201688] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/16/2021] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To compare clinical characteristics and treatment of patients with rheumatoid arthritis (RA) across 4 Canadian cohorts. METHODS The four longitudinal cohorts included: The Canadian Early Arthritis Cohort (CATCH) (n=2878); Ontario Best Practices Research Initiative (OBRI) (n=3734); RHUMADATA® (Quebec, n=2890), and the Rheum4U Precision Health Registry (Calgary, n=709). Data were from cohort inception (range 1998-2016) to 2020. Clinical characteristics and drug treatments were summarized descriptively. RESULTS 10,211 patients with RA were included. The percentage of patients who entered the cohort with early RA ( ≤ 2 years of disease at enrolment) ranged from 29% (Rheum4U) to 100% (CATCH). Mean age (55 years), sex (74% female) and seropositivity (69%) were similar between cohorts. At the time of initial disease modifying anti-rheumatic drug (DMARD) use, median disease activity scores (DAS-28) varied, ranging from 2.99 (Rheum4U) to 5.19 (CATCH), but were more similar at the time of the first DMARD switch (range:3.57-5.03), first biologic or targeted synthetic DMARD (bDAMRD, tsDMARD) use (range:4.01-4.67) and second bDAMRD or tsDMARD (range:3.71-4.39). The initial DMARD was most commonly methotrexate, either in monotherapy (32%, range:18%-40%) or dual therapy (34%, range:29%- 42%). The first DMARD switch was to another DMARD monotherapy in 20% (range:10%- 32%), dual therapy in 49% (range:39%-56%), and bDMARD or tsDMARD in 24% (range:15%- 28%). The first bDMARD was an anti-TNF in 79% (range:78%-85%). CONCLUSION Canadian RA cohorts demonstrate some heterogeneity in treatment which could reflect differences in inclusion criteria, calendar year, or regional differences. This project is a first step towards conducting harmonized analyses across Canadian RA cohorts.
Collapse
Affiliation(s)
- Glen S Hazlewood
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Claire Bombardier
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Xiuying Li
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Mohammad Movahedi
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Denis Choquette
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Louis Coupal
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Vivian Bykerk
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Orit Schieir
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Dianne Mosher
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Deborah A Marshall
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Sasha Bernatsky
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Nicole Spencer
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Dawn P Richards
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | - Laurie Proulx
- Department of Medicine, University of Calgary; Department of Community Health Sciences, University of Calgary; Arthritis Research Canada; McCaig Institute for Bone and Joint Health; Department of Medicine University of Toronto; Toronto General Research Institute; Ontario Best Practices Research Initiative (OBRI); Institute of Health Policy, Management and Evaluation, University of Toronto; Université de Montréal, CHUM; RHUMADATA®; Hospital for Special Surgery, Weill Cornell Medical College; Canadian Early Arthritis Cohort (CATCH); Department of Medicine, McGill University; Canadian Arthritis Patient Alliance. Funding: This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the Canadian Institutes of Health Research-Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAMar is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008-2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017. OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC ), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. The Rheum4U Program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie; Amgen; Bristol-Myers Squibb (BMS); Celgene; Janssen; Merck; Novartis; Pfizer;Roche; Sanofi; Sandoz; Swedish Orphan Biovitrum AB (publ) (Sobi); and Union Chimique Belge (UCB). Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli LillyCanada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada. Conflicts of interest: The following authors declare potential conflicts of interest. D Choquette: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi-Genzyme Canada. V Bykerk: Consultant for Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remainder of the authors declared no conflicts. Address correspondence to Glen Hazlewood MD PhD, , 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1
| | | | | |
Collapse
|